News & Events
Press Releases
February 6th, 2012
SanRx Pharmaceutical's DCP™ Shows Promising Results
Against Diabetes in Recent Study
SAN DIEGO, CA – February 6th, 2012 – SanRx Pharmaceuticals, Inc.® announced today that their recent study entitled Effect of Orally Administered Dipterinyl Calcium Pentahydrate (DCP™) on Oral Glucose Tolerance in DIO Mice, was accepted for publication in "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy" by Dove Medical Press. This work was carried out in collaboration with Dr. Svetlana E. Nikoulina (SanRx) and Dr. Dietmar Fuchs (Innsbruck Medical University, Austria). A copy of the paper can be accessed on the SanRx website under publications. The oral glucose tolerance test is one of the principal tests used in the diagnosis of diabetes.
"This is a significant milestone for SanRx and our research into the use of pterins to fight many of the world's most troubling diseases," commented Dr. Phillip B. Moheno, SanRx Acting President and Chief Scientist. "In addition to the fight against diabetes (projected new cases of 9.1 per 1,000 adults a year in the US), previous research has shown pterins are also valuable in the fight against cancerous tumors, hepatitis B, tuberculosis, and arthritis," added Moheno.
SanRx is currently seeking funding to continue its research and complete FDA mandated toxicology testing.
About SanRx Pharmaceuticals
Based in San Diego, California, SanRx Pharmaceuticals is the leading developer of immune-boosting compounds based on the naturally occurring human small molecule "pterin." Testing by reputable third-party laboratories substantiates the Pterin+Calcium™ and DCP™ compounds discovered by SanRx provide a strong ability to boost the human immune system against a number of disease conditions without the toxic side effects or high cost of traditional therapies. The diseases SanRx compounds Pterin+Calcium and DCP are now proving effective against in peer-reviewed published research include two types of cancerous breast tumors, hepatitis B, and Diabetes.
For more information, visit www.sanrx.com.
Company Contact:
Dr Phillip Moheno, SanRx Pharmaceuticals,
phil.moheno@sanrx.com, 858-344-9778.
Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cjcom@cableone.net, 928-273-0513.
Previous Press Releases
SanRx Demonstrates Ability To Boost The Immune System Against Tumors, Diabetes, and TB
Developmental Stage Company Seeks Funding to Complete FDA Study
October 6, 2011 – San Diego, CA
SanRx Pharmaceuticals® announced today that following positive third-party test results of their pterin-based immune system boosting compounds, Pterin+Calcium™ and DCP™, they are seeking funding to comply with a required FDA study.
The pterin-based compounds developed by SanRx Pharmaceuticals have been shown to suggest a strong ability to boost the human immune system against a number of disease conditions, including cancerous tumors, Hepatitis B, Tuberculosis and most recently Diabetes. "We are extremely pleased by the recent diabetes-study results from the Millipore Corporation (http://www.millipore.com/) and Dr. Dietmar Fuchs, of the Innsbruck Medical University in Austria," commented Dr. Phillip Moheno, SanRx Acting President and Chief Scientist. "We are eager to seize this momentum and move forward on securing FDA approval of Pterin+Calcium as a nutritional supplement," Moheno added.
SanRx is seeking an initial investment of $500,000 to cover related test costs and pending FDA clearance, develop marketing and distribution methods. About SanRx Pharmaceuticals
Based in San Diego, California, SanRx Pharmaceuticals® is the leading developer of immune-boosting compounds based on the naturally occurring human small molecule "pterin." Testing by reputable third-party laboratories substantiates that the Pterin+Calcium™ and DCP™ compounds discovered by SanRx can provide a strong ability to boost the human immune system against a number of disease conditions without the toxic side effects or high cost of traditional therapies. The diseases SanRx compounds are proving effective against include two types of cancerous breast tumors, Hepatitis B, Tuberculosis and Diabetes in model systems.
For more information, visit www.sanrx.com.
Company Contact:
Dr Phillip Moheno, SanRx Pharmaceuticals,
phil.moheno@sanrx.com, 858-344-9778.
Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cjcom@cableone.net, 928-273-0513.
Newletters
Read the Fall 2011 Newsletter »Events
May 9th-13th, 2011
15th International Symposium of Pteridines and Folates
Website: http://www.pteridinesfolates2012.org/
Past Events
October 12th-13th, 2011
SanRx attended the SupplySide West Tradeshow in Las Vegas.
Website: http://www.supplysideshow.com
SanRx was a presenter at NCN's Fall Investor Meeting.
http://www.nutritioncapital.com/